| 纯度 | > 95 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD4 |
| Uniprot No | P01730 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-396aa |
| 氨基酸序列 | KKVVLGKKGD TVELTCTASQ KKSIQFHWKN SNQIKILGNQ GSFLTKGPSK LNDRADSRRS LWDQGNFPLI IKNLKIEDSD TYICEVEDQK EEVQLLVFGL TANSDTHLLQ GQSLTLTLES PPGSSPSVQC RSPRGKNIQG GKTLSVSQLE LQDSGTWTCT VLQNQKKVEF KIDIVVLAFQ KASSIVYKKE GEQVEFSFPL AFTVEKLTGS GELWWQAERA SSSKSWITFD LKNKEVSVKR VTQDPKLQMG KKLPLHLTLP QALPQYAGSG NLTLALEAKT GKLHQEVNLV VMRATQLQKN LTCEVWGPTS PKLMLSLKLE NKEAKVSKRE KAVWVLNPEA GMWQCLLSDS GQVLLESNIK VLPTWSTPVQ P |
| 预测分子量 | 41 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与CD4重组蛋白相关的模拟参考文献(注：文献信息为示例性构建，实际引用时请核实真实文献)：
1. **文献名称**: "Recombinant Soluble CD4 Protein Blocks HIV-1 Infection in vitro"
**作者**: Smith A, et al.
**摘要**: 研究报道了重组可溶性CD4蛋白在体外实验中抑制HIV-1病毒进入宿主细胞的机制，证实其通过与病毒包膜蛋白gp120结合阻断病毒与细胞表面CD4受体的相互作用。
2. **文献名称**: "Structural Analysis of CD4 Recombinant Protein for Immunotherapy Development"
**作者**: Lee B, et al.
**摘要**: 通过X射线晶体学解析了重组CD4蛋白的三维结构，揭示了其与MHC-II分子及T细胞受体的结合位点，为基于CD4的免疫治疗药物设计提供了结构基础。
3. **文献名称**: "Engineered CD4 Fusion Proteins Enhance Anti-Tumor Immune Response"
**作者**: Zhang C, et al.
**摘要**: 开发了一种重组CD4-抗体融合蛋白，通过靶向肿瘤微环境中的抗原呈递细胞，增强T细胞活化，在小鼠模型中显著抑制肿瘤生长并延长生存期。
如需真实文献，建议通过PubMed或Google Scholar检索关键词如"recombinant CD4 protein"、"soluble CD4 immunotherapy"等，并筛选近年高影响力期刊论文。
**Background of CD4 Recombinant Protein**
CD4 is a glycoprotein expressed primarily on the surface of helper T cells, regulatory T cells, and certain dendritic cells. As a key co-receptor for T-cell receptor (TCR) signaling, it interacts with major histocompatibility complex class II (MHC II) molecules on antigen-presenting cells, stabilizing TCR-antigen binding and enhancing immune activation. Structurally, CD4 comprises four extracellular immunoglobulin-like domains (D1-D4), a transmembrane region, and a cytoplasmic tail involved in intracellular signaling.
The CD4 protein gained significant attention due to its role in HIV infection. HIV-1 envelope glycoprotein gp120 binds to CD4 as the initial step of viral entry, making CD4 a critical target for therapeutic interventions. Recombinant CD4 proteins, engineered through genetic modification and produced in systems like mammalian or bacterial cells, mimic the extracellular domains of native CD4. These proteins are designed to block HIV entry by competitively binding gp120. preventing viral attachment to host cells.
In the 1980s–1990s, recombinant soluble CD4 (sCD4) was explored as an HIV therapy but showed limited efficacy due to low potency and short half-life. However, advancements led to engineered variants, such as CD4-IgG fusion proteins (e.g., PRO 542) or CD4-based CAR-T cells, which improved antiviral activity. Beyond HIV, recombinant CD4 proteins serve as tools to study T-cell activation mechanisms, autoimmune diseases, and immune evasion strategies of pathogens.
Challenges remain in optimizing stability, affinity, and delivery methods. Current research focuses on bispecific constructs, combination therapies, and structural modifications to enhance clinical utility. Overall, recombinant CD4 proteins continue to bridge foundational immunology with translational applications in infectious diseases and immunotherapy.
×
